These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 10905756)

  • 1. Interferon beta1a therapy changes lipoprotein metabolism in patients with multiple sclerosis.
    Sena A; Pedrosa R; Ferret-Sena V; Almeida R; Andrade ML; Morais MG; Couderc R
    Clin Chem Lab Med; 2000 Mar; 38(3):209-13. PubMed ID: 10905756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of niceritrol (pentaerythritol tetranicotinate) on plasma lipoprotein concentration: increment of high density lipoprotein(HDL) cholesterol and HDL-cholesterol/low density lipoprotein cholesterol ratio in hypo-high density lipoproteinemia.
    Oida K; Nakai T; Tamai T; Kutsumi Y; Kobayashi T; Hayashi T; Yamada S; Takeda R
    Artery; 1982; 10(4):266-85. PubMed ID: 7181672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein changes in children after liver transplantation: mild hypertriglyceridemia and a decrease in HDL3/HDL2 ratio.
    Granot E
    Hepatology; 1998 Jan; 27(1):175-80. PubMed ID: 9425934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Modifications of the lipid metabolism induced by interferon beta in multiple sclerosis patients and its relationship with the disease activity].
    Ara JR; López A; Martín J; Alarcia R; Oliván JA; de Val V
    Neurologia; 2004 Sep; 19(7):359-63. PubMed ID: 15273882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining interferon beta response status in multiple sclerosis patients.
    Rudick RA; Lee JC; Simon J; Ransohoff RM; Fisher E
    Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
    Julve J; Escolà-Gil JC; Rotllan N; Fiévet C; Vallez E; de la Torre C; Ribas V; Sloan JH; Blanco-Vaca F
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):232-8. PubMed ID: 19910634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the metabolic tolerance in postmenopausal women over a 1-year period of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.
    Meuwissen JH; Beijers-De Bie L; Vihtamaki T; Tuimala R; Siseles N; Magaril C; The HS; Houben PW; Murga M; Spielmann D; De Villiers TJ
    Gynecol Endocrinol; 2002 Apr; 16(2):155-62. PubMed ID: 12012627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
    Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P
    Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroxine binding to the apolipoproteins of high density lipoproteins HDL2 and HDL3.
    Benvenga S; Cahnmann HJ; Rader D; Kindt M; Robbins J
    Endocrinology; 1992 Dec; 131(6):2805-11. PubMed ID: 1446618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of short-term modest weight loss on fasting and post-prandial lipoprotein sub-fractions in type 2 diabetes mellitus patients.
    Ybarra J; James RW; Makoundou V; Bioletto S; Golay A
    Diabetes Metab; 2001 Dec; 27(6):701-8. PubMed ID: 11852380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon treatment for multiple sclerosis patients in Hong Kong.
    Lau KK; Lee PO; Chan KY; Chan YW; Chin KF
    Hong Kong Med J; 2000 Jun; 6(2):221-3. PubMed ID: 10895148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High density lipoprotein and diabetes mellitus.
    Tanaka A; Uchimura I; Maezawa H
    Bull Tokyo Med Dent Univ; 1984 Jun; 31(2):85-91. PubMed ID: 6430582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein metabolism in patients with elevated lipoprotein-lipase activity in adipose tissue.
    Enzi G; Martini S; Baggio G; Baldo G; Digito M; Zanella A
    Int J Obes; 1985; 9 Suppl 1():173-6. PubMed ID: 4066122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment.
    Guerrero AL; Martín-Polo J; Laherrán E; Gutiérrez F; Iglesias F; Tejero MA; Rodríguez-Gallego M; Alcázar C
    Eur J Neurol; 2008 Apr; 15(4):394-7. PubMed ID: 18312403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis.
    Røsjø E; Myhr KM; Løken-Amsrud KI; Bakke SJ; Beiske AG; Bjerve KS; Hovdal H; Lilleås F; Midgard R; Pedersen T; Benth JS; Torkildsen Ø; Wergeland S; Michelsen AE; Aukrust P; Ueland T; Holmøy T
    J Neuroimmunol; 2014 Jun; 271(1-2):60-5. PubMed ID: 24713402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A one-year study on the pharmacodynamic profile of interferon-beta1a in MS.
    Bagnato F; Pozzilli C; Scagnolari C; Bellomi F; Pasqualetti P; Gasperini C; Millefiorini E; Galgani S; Spadaro M; Antonelli G
    Neurology; 2002 May; 58(9):1409-11. PubMed ID: 12011292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.